<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Methotrimeprazine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01403</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01403/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01403/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01403.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01403.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01403.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01403.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01403.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01403">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-Methoxytrimeprazine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Levomepromazine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Levoprome</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Neurocil</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nosinan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Nozinan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antipsychotic-agents">Antipsychotic Agents</a></li>
<li><a href="/mesh/analgesics-non-narcotic">Analgesics, Non-Narcotic</a></li>
<li><a href="/mesh/dopamine-antagonists">Dopamine Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>60-99-1</td></tr><tr><th>Weight</th><td>Average: 328.472<br>Monoisotopic: 328.16093409</td></tr><tr><th>Chemical Formula</th><td>C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>OS</td></tr><tr><th>InChI Key</th><td>VRQVVMDWGGWHTJ-CQSZACIVSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">[(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-2-methylpropyl]dimethylamine</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC2=C(SC3=C(C=CC=C3)N2C[C@H](C)CN(C)C)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzothiazines</td></tr><tr><th>Subclass</th><td>Phenothiazines</td></tr><tr><th>Direct parent</th><td>Phenothiazines</td></tr><tr><th>Alternative parents</th><td>Anisoles; Alkyl Aryl Ethers; Tertiary Amines; Polyamines; Thioethers</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; alkyl aryl ether; benzene; tertiary amine; thioether; polyamine; ether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.</td></tr><tr><th>Pharmacodynamics</th><td>Methotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604)</td></tr><tr><th>Mechanism of action</th><td>Methotrimeprazine's antipsychotic effect is largely due to its antagonism of dopamine receptors in the brain. In addition, its binding to 5HT2 receptors may also play a role. </td></tr><tr><th>Absorption</th><td>Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver. Oral bioavailability is approximately 50 to 60%.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid- and a demethyl-moiety.</p></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Approximately 20 hours.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include convulsions, spastic movements, and coma.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9857</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9935</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.6694</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6805</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8564</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8571</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5132</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7511</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.5363</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6056</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6953</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.8932</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.5432</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5633</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5562
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9182
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5064 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.932
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8488
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Immunex corp</li></ul></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Intramuscular</td><td></td></tr><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00182">Amphetamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00865">Benzphetamine</a></td><td>Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines. </td></tr><tr><td><a href="/drugs/DB00484">Brimonidine</a></td><td>Brimonidine may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of brimonidine. Consider therapy modification. </td></tr><tr><td><a href="/drugs/DB01558">Bromazepam</a></td><td>Concomitant therapy may result in additive CNS depressant effects. The dosage of bromazepam should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression. </td></tr><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00395">Carisoprodol</a></td><td>Carisoprodol, a CNS depressant, may enhance the CNS depressant effect of methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants like carisoprodol. Reduce the dosage of CNS depressants by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose has been established. Monitor for increased CNS depression with concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01219">Dantrolene</a></td><td>Concomitant therapy may result in additive CNS depressant effects. The dosage of dantrolene should be decreased by 50% prior to initiating concomitant therapy. Monitor for increased CNS depression.</td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01576">Dextroamphetamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00937">Diethylpropion</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01044">Gatifloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00365">Grepafloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01170">Guanethidine</a></td><td>Methotrimeprazine may decrease the effect of guanethidine.</td></tr><tr><td><a href="/drugs/DB01247">Isocarboxazid</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01137">Levofloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00579">Mazindol</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01577">Methamphetamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB01578">Metrizamide</a></td><td>Increased risk of convulsions</td></tr><tr><td><a href="/drugs/DB01267">Paliperidone</a></td><td>The CNS depressant agents, paliperidone and methotrimeprazine, may cause additive CNS depressant effects. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01626">Pargyline</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01579">Phendimetrazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00780">Phenelzine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB00830">Phenmetrazine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00191">Phentermine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>Decreased anorexic effect, may increase psychotic symptoms</td></tr><tr><td><a href="/drugs/DB00989">Rivastigmine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01208">Sparfloxacin</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Additive CNS depressant effects. Decrease dose of tramadol by 50% if initiating methotrimeprazine therapy. Monitor for increased CNS depression and apply further dosage adjustments as required. </td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Possible severe adverse reaction with this combination</td></tr><tr><td><a href="/drugs/DB01080">Vigabatrin</a></td><td>Additive CNS depression may occur. Dose adjustments may be required if one agent is added to existing therapy with the other agent. Monitor for increased CNS depression during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00962">Zaleplon</a></td><td>Additive CNS depressant effects may occur. A dose reduction of zaleplon may be required. Monitor for increased CNS depression during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB06283">Ziconotide</a></td><td>Additive CNS depressant effects may occur. A dose reduction of ziconotide may be required. Monitor for increased CNS depression during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00425">Zolpidem</a></td><td>Additive CNS depressant effects. Reduce zolpidem dose by half upon initiation of methotrimeprazine. Zolpidem dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression. </td></tr><tr><td><a href="/drugs/DB00909">Zonisamide</a></td><td>Additive CNS depressant effects. Reduce zonisamide dose by half upon initiation of methotrimeprazine. Zonisamide dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.</td></tr><tr><td><a href="/drugs/DB01198">Zopiclone</a></td><td>Additive CNS depressant effects. Reduce zopiclone dose by half upon initiation of methotrimeprazine. Zopiclone dose may be adjusted once methotrimeprazine dose has been established. Monitor for increased CNS depression.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). Methotrimeprazine, a strong CYP2D6 inhibitor, may increase the serum concentration of zuclopenthixol by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of zuclopenthixol if methotrimeprazine is initiated, discontinued or dose changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>